Core Insights - American Oncology Network (AON) is expanding access to Bispecific T-cell Engager (BiTE) therapy across more than 40 partner clinics in 18 states and Washington, D.C., enhancing treatment options for hard-to-treat cancers [1][4] - Bispecific therapies represent a significant advancement in cancer treatment by engaging the immune system to target cancer cells more effectively [2][7] - AON's commitment to integrating innovative therapies like bispecific antibodies into their offerings aims to improve patient outcomes for challenging cancers [3][9] Company Overview - AON is a rapidly growing network of community oncology practices, founded in 2018, representing over 290 providers across 21 states [11] - The organization focuses on value-based care, aiming to improve patient outcomes while reducing costs and expanding access to quality care [11] - AON is dedicated to promoting health equity and addressing disparities in cancer care, ensuring all patients have access to necessary treatments [11] Treatment Details - Bispecific therapies work by dual targeting, engaging T cells to increase immune activity at tumor sites, and enhancing the immune response while minimizing damage to healthy tissue [7] - Since March 2025, AON has provided bispecific antibody therapy for various cancers, including acute lymphoblastic leukemia and multiple myeloma [3][4] - AON's implementation of BiTE therapies allows patients to receive advanced treatments in community settings, reducing the need for travel to major medical centers [4][9] Clinical Trials and Research - AON actively participates in clinical trials and collaborates with leading researchers to explore new applications of bispecific antibodies in oncology [8]
More Than 40 American Oncology Network Clinics Across 18 States and Washington, D.C., Now Offering Bispecific T-cell Engager Therapies to Patients